Ciphergen Faces Nasdaq Delisting for Low Market Cap | GenomeWeb

NEW YORK, June 1 (GenomeWeb News) - The Nasdaq exchange told Ciphergen Biosystems last week that it risks being delisted because its market cap has remained below $50 million for 10 consecutive business days.

 

Ciphergen yesterday said it has until June 23 to regain compliance. Its market cap currently stands at $41.4 million, according to Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.